Who Exports Tinidazole from India — 315 Suppliers Behind a $18.4M Market
India's tinidazole export market is supplied by 315 active exporters who collectively shipped $18.4M across 2,271 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 11.9% market share, followed by VANSH REMEDIES and CIPLA LIMITED. The top 5 suppliers together control 42.7% of total export value, reflecting a moderately competitive market structure.
Top Tinidazole Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading tinidazole exporter from India, holding a 11.9% share of the $18.4M market across 2,271 shipments from 315 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED, VANSH REMEDIES, CIPLA LIMITED, MICRO LABS LIMITED, CAPLIN POINT LABORATORIES LIMITED — collectively control 42.7% of total export value, indicating a competitive market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (11.9%), VANSH REMEDIES (9.6%), CIPLA LIMITED (8.5%), MICRO LABS LIMITED (8.3%), CAPLIN POINT LABORATORIES LIMITED (4.3%).
Top Tinidazole Exporters from India
Ranked by export value · 315 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,NORFLOXACIN WITH TINIDAZOLE TABLETS ( NONORFLOXACIN WITH TINIDAZOLE TABLETS NOS | $2.2M | 6 | 11.9% |
| 2 | VANSH REMEDIES TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,NORFLOXACIN WITH TINIDAZOLE TABLETS ( NONORFLOXACIN WITH TINIDAZOLE TABLETS NOS | $1.8M | 1 | 9.6% |
| 3 | CIPLA LIMITED PYLOKIT [52920X7X1X6'S]PYLOKIT [52653X7X1X6'S]PYLOKIT [50022X7X1X6'S] | $1.6M | 3 | 8.5% |
| 4 | MICRO LABS LIMITED TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,INORE-KITINORE-KIT -TAX INV NO: | $1.5M | 11 | 8.3% |
| 5 | CAPLIN POINT LABORATORIES LIMITED CIPROFLOXACIN AND TINIDAZOLE TABLETS (CICIPTIN FORTE (CIPROFLOXACIN 500MG+TINIDAZOLE 600MG TABLETSCIPROFLOXACIN AND TINIDAZOLE TABLETS CIPTIN FORTE | $788.3K | 6 | 4.3% |
| 6 | ZYDUS LIFESCIENCES LIMITED TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,PYLOKIT [52920X7X1X6'S]PYLOKIT [52653X7X1X6'S] | $522.8K | 9 | 2.8% |
| 7 | INTAS PHARMACEUTICALS LIMITED TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,PYLOKIT [52920X7X1X6'S]PYLOKIT [52653X7X1X6'S] | $425.8K | 3 | 2.3% |
| 8 | LINCOLN PHARMACEUTICALS LTD TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,PYLOKIT [52920X7X1X6'S]PYLOKIT [52653X7X1X6'S] | $383.3K | 5 | 2.1% |
| 9 | MEDICO REMEDIES LIMITED GECIP -TN CIPROFLOXACIN & TINIDAZOLE TAGECIP -TN --29 PACKS :TINIDAZOLE TABLETS BP 500 MG P | $379.6K | 6 | 2.1% |
| 10 | ZEST PHARMA TZEX-500 TAB TINIDAZOLE TABLET | $335.9K | 1 | 1.8% |
| 11 | J B CHEMICALS AND PHARMACEUTICALS LIMITED 29 PACKS :TINIDAZOLE TABLETS BP 500 MG PTZEX-500 TAB TINIDAZOLE TABLET | $301.0K | 1 | 1.6% |
| 12 | INNOVA CAPTAB LIMITED TZEX-500 TAB TINIDAZOLE TABLET | $297.0K | 2 | 1.6% |
| 13 | V S INTERNATIONAL PRIVATE LIMITED TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,CIPROFLOXACIN AND TINIDAZOLE TABLETS (CIINORE-KIT | $296.0K | 2 | 1.6% |
| 14 | SCOTT EDIL PHARMACIA LIMITED PYLOKIT [52920X7X1X6'S]PYLOKIT [52653X7X1X6'S]PYLOKIT [50022X7X1X6'S] | $263.8K | 5 | 1.4% |
| 15 | BRAWN LABORATORIES LIMITED TINI-VAN- TINIDAZOLE TABLETS BP 500 MG,INORE-KITINORE-KIT -TAX INV NO: | $259.8K | 9 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Tinidazole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter issued Jun | Yes, as of 2023 | Yes | Multiple | FDA cited CGMP violations at Dadra facility in June 2024. |
| Cipla Limited | Warning Letter issued Nov | Yes, as of 2023 | Yes | Multiple | FDA cited CGMP violations at Indore facility in November 2023. |
| Micro Labs Limited | Warning Letter issued Jan | Yes, as of 2023 | Yes | Multiple | FDA cited data integrity issues at Bangalore facility in January 2015. |
| Zydus Lifesciences Limited | Approved | Yes, as of 2023 | Yes | Multiple | No FDA warning letters; holds multiple ANDAs. |
| Intas Pharmaceuticals Limited | Approved | Yes, as of 2023 | Yes | Multiple | No FDA warning letters; holds multiple ANDAs. |
| Lincoln Pharmaceuticals Ltd | Approved | Yes, as of 2023 | Yes | Multiple | No FDA warning letters; holds multiple ANDAs. |
| Medico Remedies Limited | Approved | Yes, as of 2023 | Yes | Multiple | No FDA warning letters; holds multiple ANDAs. |
| J B Chemicals and Pharmaceuticals Limited | Approved | Yes, as of 2023 | Yes | Multiple | No FDA warning letters; holds multiple ANDAs. |
| Brawn Laboratories Limited | Approved | Yes, as of 2023 | Yes | Multiple | No FDA warning letters; holds multiple ANDAs. |
TransData Nexus reviewed the regulatory standing of 9 leading Tinidazole exporters from India. 6 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Tinidazole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. This concentration of expertise and infrastructure makes Hyderabad a critical center for API manufacturing, including Tinidazole.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses major companies like Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's robust infrastructure, including ports and transportation networks, supports efficient manufacturing and distribution of pharmaceutical products, including Tinidazole formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a significant export gateway for pharmaceuticals. With 929 pharmaceutical units, Maharashtra is a key player in India's pharmaceutical exports. The region's proximity to major ports facilitates the efficient export of pharmaceutical products, including Tinidazole, to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh form one of Asia's largest pharmaceutical hubs, housing over 550 pharmaceutical units. The region's growth has been significantly influenced by favorable tax incentives, attracting numerous pharmaceutical companies. Baddi's strategic location and industrial infrastructure make it a vital area for pharmaceutical manufacturing, including Tinidazole.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance standards of suppliers in Hyderabad for APIs and in Ahmedabad-Vadodara for formulations.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline international distribution of Tinidazole products.
- Consider Cost Advantages: Explore manufacturing opportunities in Baddi-Nalagarh to benefit from tax incentives and cost-effective production.
By strategically sourcing from these clusters, TransData Nexus can optimize its supply chain for Tinidazole, ensuring quality, cost-effectiveness, and reliability.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Tinidazole exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's dermatology portfolio, potentially increasing its production capacity and export capabilities for products like Tinidazole.
Impact: This acquisition is expected to enhance Sun Pharma's dermatology portfolio, potentially increasing its production capacity and export capabilities for products like Tinidazole.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma announced the acquisition of Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments, for $355 million. - IMPACT: While primarily focused on oncology, this acquisition may lead to expanded research and development capabilities, indirectly benefiting the production and export of Tinidazole.
Impact: While primarily focused on oncology, this acquisition may lead to expanded research and development capabilities, indirectly benefiting the production and export of Tinidazole.
Sun Pharmaceutical Industries Limited — Sun Pharma open to exploring acquisitions in global specialty portfolio
Sun Pharma's Chairman and Managing Director, Dilip Shanghvi, stated that the company, with a net cash position of $2.4 billion, is open to exploring acquisitions to strengthen its global specialty portfolio. - IMPACT: Potential future acquisitions could enhance Sun Pharma's manufacturing capabilities, positively affecting Tinidazole export volumes.
Impact: Potential future acquisitions could enhance Sun Pharma's manufacturing capabilities, positively affecting Tinidazole export volumes.
Common Questions — Tinidazole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which tinidazole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 23 recorded shipments worth $2.2M. VANSH REMEDIES (3 shipments) and CIPLA LIMITED (29 shipments) are also established high-volume exporters.
Q How many tinidazole manufacturers are there in India?
India has 315 active tinidazole exporters with a combined export market of $18.4M across 2,271 shipments to 105 countries. The top 5 suppliers hold 42.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for tinidazole from India?
Average FOB unit price: $3.92 per unit, ranging from $0.00 to $566.17. Average shipment value: $8.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 315 verified Indian exporters of Tinidazole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,271 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 105 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,271 Verified Shipments
315 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists